Creating a long-lasting HIV vaccine that targets the mucosal surfaces of the body.
Durable HIV Vaccine Targeting Mucosal Epithelium
This study is working on a new HIV vaccine that aims to protect you right where the virus first enters your body, helping your immune system stay ready to fight off HIV both now and in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Biomedical Research Institute NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10892154 on NIH RePORTER |
What this research studies
This research focuses on developing a durable HIV vaccine that targets mucosal tissues, which are the initial entry points for the virus. The approach aims to stimulate the immune system continuously with viral antigens to maintain a heightened state of alert against HIV. By utilizing epithelial stem cells to deliver these antigens, the vaccine seeks to elicit strong immune responses at the site of potential infection, thereby enhancing the body's ability to resist HIV. The goal is to provide both immediate and long-term protection against the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of HIV exposure or those who are HIV-negative but may benefit from preventive measures.
Not a fit: Patients who are already HIV-positive or those with compromised immune systems may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective HIV vaccine that provides long-lasting immunity and significantly reduces the risk of infection.
How similar studies have performed: Previous research has shown promise in developing vaccines targeting mucosal immunity, but this specific approach is innovative and largely untested.
Where this research is happening
San Antonio, United States
- Texas Biomedical Research Institute — San Antonio, United States (Active)
Researchers
- Principal investigator: Gauduin, Marie-Claire Elisabeth — Texas Biomedical Research Institute
- Study coordinator: Gauduin, Marie-Claire Elisabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.